Keywords: ازتیمایب; Ezetimibe; Hypoxia; Atherosclerosis; Oxidative stress; Ultrastructure;
مقالات ISI ازتیمایب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ازتیمایب; Dyslipidemia; Electronegative low-density lipoprotein; Oxidized LDL; Statins; Ezetimibe
Keywords: ازتیمایب; Ezetimibe; Diabetes; Monotherapy; Lipid targets;
Keywords: ازتیمایب; Simvastatin; Ezetimibe; Chylomicrons; Triglyceride-rich lipoproteins; Emulsions; ApoB-48;
Keywords: ازتیمایب; ezetimibe; rearrangement; azetidinone; NMR; kinetics; Liquid chromatography; acid-base catalysis; pH rate profile; chemical stability; degradation products; UV-VIS spectroscopy;
Keywords: ازتیمایب; Cholesterol; Ezetimibe; Hypercholesterolemia; LDL-C; Lipids; Lipoprotein; Statin;
Keywords: ازتیمایب; Chocolate; Ezetimibe; Plant sterol; Statin; Oxidative stress; oxLDL-C;
Keywords: ازتیمایب; Statins; Resistance; Intolerance; LDL-cholesterol; Ezetimibe; PCSK9
Keywords: ازتیمایب; Statins; Ezetimibe; Campesterol; Lathosterol; β-Sitosterol; Squalene; Desmosterol; Cholestanol;
Keywords: ازتیمایب; Lipids; Cholesterol; Statin; Niacin; Fibrates; Ezetimibe; Omega-3 fatty acids; Cardiovascular risk;
Keywords: ازتیمایب; dyslipidemia; chronic liver disease; chronic kidney disease; end stage renal disease; statins; fibrates; ezetimibe
Keywords: ازتیمایب; Ezetimibe; Impurities; Isolation; HPLC; Characterization;
Keywords: ازتیمایب; Statin; LDL-C; Ezetimibe; Niacin; Fibrate; Combination therapy; PCSK9;
Keywords: ازتیمایب; Simvastatin; Ezetimibe; Rosuvastatin; Lipoprotein associated phospholipase A2; Oxidative stress; Inflammation; Isoprostanes; Oxidized LDL;
Keywords: ازتیمایب; Diabetes mellitus; Ezetimibe; Insulin resistance; Lipoprotein;
Keywords: ازتیمایب; Simvastatin; Ezetimibe; Extended ratio subtraction; Simultaneous ratio subtraction; Ratio difference and absorpotion factor;
Keywords: ازتیمایب; Ezetimibe; Reverse cholesterol transport; Cholesterol efflux; Cholesterol absorption; Fecal sterols;
Keywords: ازتیمایب; Dyslipidemia; Ezetimibe; Inflammation; Microarray; Mononuclear cells; Platelet adhesion; Statin; Thrombosis; ACE; angiotensin-converting enzyme; ACS; acute coronary syndrome; ALT; alanine aminotransferase; AST; aspartate aminotransferase; ARB; angiotensin
Keywords: ازتیمایب; Lipoprotein-associated phospholipase A2; Simvastatin; Ezetimibe; Coronary heart disease
Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial
Keywords: ازتیمایب; Ezetimibe; Statins; Coronary plaque; Chronic kidney disease; Intravascular ultrasound;
LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C
Keywords: ازتیمایب; Heterozygous familial hypercholesterolemia; LDL-Cholesterol; Target achievement; Cardiovascular disease; Statins; Ezetimibe; PCSK9 inhibitors;
Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry
Keywords: ازتیمایب; Familial hypercholesterolemia; LDL-C goal attainment; Treatment pattern; LDL-Cholesterol; Statins; Ezetimibe;
Enhancement of the dissolution and bioavailability from freeze-dried powder of a hypocholesterolemic drug in the presence of Soluplus
Keywords: ازتیمایب; ACUC; animal care and use committee; DSC; differential scanning electron microscope; EZT; ezetimibe; EZT-D4; deuterated ezetimibe; FD-EZT; freeze-dried ezetimibe; FTIR; Fourier transform infrared spectroscopy; PHY; physical mixture of ezetimibe and solupl
Niveles óptimos de colesterol en los pacientes con dislipemia. Revisión sistemática de la evidencia
Keywords: ازتیمایب; Colesterol; Estatina; Ezetimiba; Inhibidores PCSK9; Cholesterol; Statin; Ezetimibe; PCSK9 inhibitors;
Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial
Keywords: ازتیمایب; Simvastatin; Ezetimibe; Acute coronary syndrome; Cost-effectiveness analysis;
Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis
Keywords: ازتیمایب; Low-LDL; PCSK9 inhibitors; Ezetimibe; Lipid-lowering therapy; Low-LDL safety;
Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGHÂ trial
Keywords: ازتیمایب; Extended release niacin; Cholesterol; Ezetimibe; High-density lipoprotein; Lipoprotein subfractions; Remnant lipoproteins; Residual risk; Simvastatin;
A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE
Keywords: ازتیمایب; ezetimibe; hypercholesterolemia; rosuvastatin; singe-pill combination;
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe
Keywords: ازتیمایب; NAFLD; Ezetimibe; Statin; Acute coronary syndrome; Cardiovascular disease; Metabolic syndrome; Low-density lipoprotein cholesterol; Fatty liver;
Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER
Keywords: ازتیمایب; Sitosterol; Ezetimibe; Pitavastatin; Lipid-lowering; Acute coronary syndrome;
Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER)
Keywords: ازتیمایب; Clinical trial; Ezetimibe; Pitavastatin; Lipid-lowering; Acute coronary syndrome;
A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin
Keywords: ازتیمایب; Ezetimibe; Rosuvastatin; Intensive lipid-lowering therapy;
Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial
Keywords: ازتیمایب; Atorvastatin; Ezetimibe; IVUS; iMap;
Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients
Keywords: ازتیمایب; Chronic kidney disease; DNA methylation; Ezetimibe; Methylcytosine; Oxidative stress; Simvastatin; All; allantoin; CKD; chronic kidney disease; EZE; ezetimibe; MDA; malondialdehyde; mCyt; methylcytosine; OS; oxidative stress; UA; uric acid;
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
Keywords: ازتیمایب; acute coronary syndrome; ezetimibe; low-density lipoprotein cholesterol; risk stratification; secondary prevention; simvastatin; 2°P; secondary prevention; ACS; acute coronary syndrome; CABG; coronary artery bypass grafting; CV; cardiovascular; IHD; isch
Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk
Keywords: ازتیمایب; cardiovascular diseases; cholesterol; drug combinations; ezetimibe; LDL; rosuvastatin calcium;
Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects
Keywords: ازتیمایب; ezetimibe; fixed-dose combination; pharmacokinetics; rosuvastatin;
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
Keywords: ازتیمایب; Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH); Hepatocellular cancer (HCC); Statins; Ezetimibe; Pioglitazone;
“Ghost peaks” of ezetimibe: Solution degradation products of ezetimibe in acetonitrile induced by alkaline impurities from glass HPLC vials
Keywords: ازتیمایب; Ezetimibe; Base-catalyzed; Degradation; LC-MS; HPLC vial;
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Keywords: ازتیمایب; ACC Expert Consensus Decision Pathway; ASCVD; bile acid sequestrants; cholesterol; dyslipidemia; ezetimibe; LDL-C; lipids; PCSK9 inhibitors; statins;
Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters
Keywords: ازتیمایب; Ezetimibe (PubChem CID: 150311); Lovastatin (PubChem CID: 53232); Lovastatin hydroxyacid (PubChem CID: 64727); Eudragit L100® (PubChem CID: 6658); Eudragit L100-55® (PubChem CID: 107665); Ezetimibe; Lovastatin; Amorphous solid dispersions; Fixed dose co
Ãzétimibe : plus de preuves pour un effet sur la réduction du risque cardiovasculaire
Keywords: ازتیمایب; Ãzétimibe; LDL-cholestérol; cardiovasculaire; infarctus du myocarde; NCP1L1; Ezetimibe; LDL-cholesterol; cardiovascular - myocardial infarction; NCP1L1;
Electrochemical determination of ezetimibe by MgO nanoflakes-modified carbon paste electrode
Keywords: ازتیمایب; Ezetimibe; MgO nanoflakes; Modified carbon paste electrode; Cyclic voltammetry; Differential pulse voltammetry
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial
Keywords: ازتیمایب; Ezetimibe; Statin; Plaque; Intravascular ultrasound; Lipoprotein;
Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial
Keywords: ازتیمایب; Lipids; Cholesterol; Statin; Ezetimibe; Clinical trials; SHARP; Older adults; Kidney disease; Guidelines;
Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in NonâFamilial Hypercholesterolemia
Keywords: ازتیمایب; Ezetimibe; PCSK9 inhibitor; Risk reduction; ASCVD; Atherosclerotic cardiovascular disease; CVD; Cardiovascular disease; DM; Diabetes mellitus; FH; Familial hypercholesterolemia; HDL-C; High-density lipoprotein cholesterol; LDL-C; Low-density lipoprotein c
Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy
Keywords: ازتیمایب; Atorvastatin; Ezetimibe; HDL-C; hsCRP; Hypercholesterolemia; Vytorin;
Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis
Keywords: ازتیمایب; Lomitapide; Homozygous familial hypercholesterolemia; Aortic valve disease; Statins; Ezetimibe; Lipoprotein apheresis; Italy;
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial
Keywords: ازتیمایب; ezetimibe; low-density lipoprotein cholesterol; simvastatin; total events; ACS; acute coronary syndrome; CV; cardiovascular; LDL-C; low-density lipoprotein cholesterol; MI; myocardial infarction; PCI; percutaneous coronary intervention; PEP; primary endp
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Keywords: ازتیمایب; Alirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin;